Comparison of diagnostic methods for detection of BRAFV600E mutation in ameloblastoma.
Arularasan AnbinselvamAbdul-Warith O AkinshipoAkinyele Olumuyiwa AdisaOlajumoke A EffiomXinhe ZhuKehinde E AdebiyiGodwin T ArotibaSunday O AkintoyePublished in: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (2024)
Low-cost and less vulnerability of IHC to tissue quality make it a viable surrogate test for BRAFV600E detection in ameloblastoma. Sequential dual IHC and molecular testing for BRAFV600E will reduce equivocal results that could exclude some patients from BRAFV600E-inhibitor therapies.